Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.International Biotechnology Center "Generium", (LLC IBC Generium), has selected Goodwin Biotechnology for the assay and process technology transfer, process scale-up, and cGMP manufacturing of an IgG-based, bispecific antibody to support early stage clinical trials.
Subscribe to our email newsletter
IBC Generium chief business officer Daniil Talyanskiy said: "Our scientific staff at IBC Generium developed GNR-047, an IgG-based anti-CD3 / anti-CD19 bispecific antibody for the treatment of oncohematological diseases, such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and different kinds of non-Hodgkin’s lymphoma (NHL), and we were looking to partner with a Contact Manufacturing Organization to help us optimize the process and manufacture material to be used in Phase I clinical trials.
"We work with a number of companies around the world to advance our portfolio of drug candidates, and one of our primary collaborators highly recommended Goodwin Biotechnology based on the track record they had on a number of their projects that Goodwin Biotechnology had worked on over the last six years."
Goodwin Biotechnology COO SooYoung S. Lee said: "Our highly skilled scientists take great pride in working with our clients to enhance the value of their product candidates.
"We are excited to be working on IBC Generium’s cutting edge bispecific antibody, bringing to bear our multiple decades of experience in this field. And, the fact that we have been referred by one of our long-term, satisfied clients to IBC Generium gives us immense pride; it is a validation of the technical expertise, commitment, and dedication of our staff. Our clients appreciate our creative and flexible approach in forging partnerships with them and taking the time to listen to their challenges, then developing a customized strategy to cost effectively address their needs and deliver their product on time."
IBC Generium is a private scientific research and development company founded in Russia in 2011.
It is a rapidly growing company brings together leading Russian scientists, including those living abroad, professionals with advanced skills and cutting-edge scientific knowledge to work on discovery and development of innovative biotechnology-based therapeutics.